Brandenburg Kapital - News about SphingoTec GmbH
SphingoTec closes €5M series C for further international market entry with their innovative biomarkers
Hennigsdorf – August 2024. SphingoTec GmbH has successfully secured funding that will be used to establish SphingoTec’s biomarkers in international comprehensive patient care, on the basis of strategic partnerships with established providers of diagnostic platforms.
The lead investor, Think.Health Ventures, specializes in healthcare ventures that focus on innovations and business models in digital healthcare, medical technologies, and health service providers. Additionally, SphingoTec has secured support from existing investors, which also include Brandenburg Kapital, HBM Healthcare Investments, NRW.BANK, and Wellington Partners.
SphingoTec develops and markets innovative in-vitro-diagnostic solutions for novel biomarkers for intensive care. The biomarkers provide important, organ-specific information for monitoring acute disease progressions such as sepsis or acute renal failure. In doing so, they support clinical decisions with the aim of improving patient care and management.
Brandenburg Kapital GmbH has been supporting the company since 2018.
Read the full press release here.
For more information, please visit: www.brandenburg-kapital.de, www.sphingotec.com